share_log

NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today

NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today

NURO股票:“突破性”消息推动NeuroMetrix股价今日飙升
InvestorPlace ·  2021/07/20 11:03

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace-股市新闻、股票咨询和交易提示

NeuroMetrix (NASDAQ:NURO) stock is surging higher on Tuesday after getting “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA).

神经间质纳斯达克股票代码:NURO)股价周二大幅上涨,此前该公司获得了美国食品和药物管理局(FDA)的“突破性设备称号”。

Source: Shutterstock
消息来源:Shutterstock

The breakthrough designation is for NeuroMetrix’s Quell device designed to treat symptoms in adult patients suffering from fibromyalgia. This is due to the unmet need for managing pain from fibromyalgia without pharmacological treatments.

这一突破性的设计是为NeuroMetrix的Quell设备设计的,该设备旨在治疗患有纤维肌痛的成年患者的症状。这是由于在没有药物治疗的情况下,对纤维肌痛的疼痛管理的需求没有得到满足。

While there are medicines to treat the pain of fibromyalgia, NeuroMetrix seeks to help manage it further with Quell. The device is only the size of a credit card and can connect to the company’s app via Bluetooth to assist with fibromyalgia managment.

虽然有治疗纤维肌痛的药物,但NeuroMetrix寻求通过Quell进一步帮助管理它。该设备只有信用卡大小,可以通过蓝牙连接到该公司的应用程序,帮助治疗纤维肌痛。

It’s worth pointing out that the designation for Quell comes after a clinical trial. This double-blind study saw 119 patients enrolled. Of those on Quell, 56% reported a clinically meaningful improvement in health-related quality-of-life. For comparison, only 35% achieved that in the sham group.

值得一提的是,Quell的名称是在临床试验之后才被指定的。这项双盲研究共有119名患者参加。在服用奎尔的患者中,56%的人报告说,与健康相关的生活质量在临床上有了有意义的改善。相比之下,在假手术组中,只有35%的人做到了这一点。


  • 7 'A-Rated' Small-Cap Stocks to Buy Now

  • 7只‘A级’小盘股现在买入

Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix, had the following to say about the news sending NURO stock higher today.

NeuroMetrix公司总裁兼首席执行官、医学博士Shai N.Gozani就今天推动NURO股价上涨的消息发表了以下言论。

“The Breakthrough Device Designation is an important milestone in the Company’s effort to make Quell technology available to people living with fibromyalgia. We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.”

突破性设备的指定是该公司向纤维肌痛患者提供Quell技术的努力中的一个重要里程碑。我们正在推进一份监管申报文件,这可能会让我们在明年下半年推出Quell,以应对这一迹象。“

To go along with this news, NURO stock is seeing incredibly heavy trading today. As of this writing, more than 37 million shares of the stock have changed hands. That’s quite the increase compared to its daily average trading volume of around 114,000 shares.

为了配合这一消息,NURO股票今天的交易量令人难以置信。截至撰写本文时,该股已有超过3700万股易手。与其约11.4万股的日均成交量相比,这是相当大的增幅。

NURO stock was up 42.6% as of Tuesday morning.

截至周二上午,NURO股价上涨42.6%。

Of course, there is more going on with the market today that’s worth looking into.

当然,今天的市场还有更多值得关注的地方。

Luckily, InvestorPlace has it covered. That includes the latest stock news concerning Peloton (NASDAQ:PTON), Ardelyx (NASDAQ:ARDX), and Nvidia (NASDAQ:NVDA). You can learn all about this at the links below!

幸运的是,InvestorPlace它被覆盖了吗。这包括最新的股票新闻,关于佩洛顿(纳斯达克股票代码:PTON),阿德莱克斯(纳斯达克:ARDX),以及英维迪亚(纳斯达克股票代码:NVDA)你可以在下面的链接上了解到这一切!

More Monday Stock Market News

更多周一股市新闻

  • PTON Stock: The UNH Deal Giving Peloton Shares a Jump Today
  • ARDX Stock: Disastrous FDA News Sends Ardelyx Shares Plummeting
  • Nvidia Stock Split 2021: What NVDA Investors Should Know as the 4-for-1 Split Goes Into Effect
  • PTON股票:UNH交易今日提振peloton股价
  • ARDX股票:FDA灾难性的消息导致Ardelyx股价暴跌
  • NVIDIA股票拆分2021年:NVDA投资者在4比1拆分生效时应该知道什么

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在出版之日,威廉·怀特没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点,以InvestorPlace.com为准出版指南.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

除了最罕见的例外,InvestorPlace不会发布关于市值低于1亿美元或每天交易量低于10万股的公司的评论。这是因为这些“廉价股”经常是诈骗艺术家和市场操纵者的游乐场。如果我们确实发布了可能受我们的评论影响的低成交量股票的评论,我们要求 InvestorPlace.com该书的作者披露了这一事实,并警告读者其中的风险。更多阅读: 便士股票-如何在不上当的情况下获利

The post NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today appeared first on InvestorPlace.

NOEO后的股票:“突破性”新闻今天飙升的NeuroMetrix股价今天出现在InvestorPlace的首位。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发